GSK is evaluating potential cost-saving measures and manufacturing adjustments in Europe as it aims to invest in the launch of new products while moving away from older legacy drugs. City
GSK is evaluating potential cost-saving measures and manufacturing adjustments in Europe as it aims to invest in the launch of new products while moving away from older legacy drugs. City
The NHS is embarking on a significant initiative aimed at removing up to 300,000 patients from its waiting lists in an effort to streamline operations and enhance patient care. This






